VANCOUVER, BRITISH COLUMBIA--(Marketwire - September 08, 2008) - Tekmira Pharmaceuticals Corporation (TSX: TKM) announced today that one of its collaborators, the National Cancer Institute (NCI), has presented promising pre-clinical data treating liver cancer using small interfering RNA (siRNA) enabled by Tekmira’s SNALP (stable nucleic acid-lipid particles) delivery technology.
